Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United …
$1.25-10.07%
报价 2026-11-16
市值
$97.2M
EV
$204.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -62.1%
$1.18$3.30
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STIMNeuronetics, Inc. | $97.2M | -10.1% | +8.8% | 50.7% | – | – | – | |
| OABIOmniAb, Inc. | $713.3M | -0.4% | +91.2% | 63.6% | – | – | 312.2x | |
| PROFProfound Medical Corp. | $268.8M | -1.1% | – | 71.7% | – | – | – | |
| PREPrenetics Global Limited | $262.2M | -6.2% | – | 62.6% | – | – | – | |
| OSUROraSure Technologies, Inc. | $248.6M | -0.6% | +4.4% | 41% | – | – | – | |
| CDXSCodexis, Inc. | $116.2M | -8.6% | +10.1% | 79.5% | – | – | – | |
| CATXPerspective Therapeutics, Inc. | $111.6M | -2.0% | -54.5% | -419.4% | – | – | – | |
| NYXHNyxoah S.A. | $91M | -0.6% | – | 51.3% | – | – | – | |
| 同行中位数 | – | – | +7.2% | 62.6% | – | – | 312.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。